Beth Overmoyer, MD

Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 Dana Faber InstituteBoston, Massachusetts - 02115 |
- CLINICAL TRIALS 2
- CONDITIONS1
- INTERVENTIONS3
- SINCE2009

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
November 2009 - October 2012

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
July 2009 - September 2011
Breast Neoplasms
Temozolomide
Abt-888
Tki258



